Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...

Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...